Phase 1
Seattle Genetics dosed its first patient with an early-stage treatment for patients with relapsed or refractory multiple myeloma (MM).
In its IPO announcement last week Unum revealed early data from its Phase I non-Hodgkin lymphoma therapy that included toxicity concerns at higher dosing levels.
A new gene therapy to treat a debilitating eye disorder is one step closer to regulatory approval in Europe.
Late Thursday the companies touted biomarker data from an early-stage study that showed the drug lowered the disease-causing protein in people with the disease.
Galera Therapeutics has initiated its Phase I/II clinical trial of GC4419 in locally advanced pancreatic cancer (LAPC).
Since Emma Walmsley took over leadership at Glaxo, expectations have been both high and hypercritical.
Along with lampalizumab, Roche announced it was culling several drug programs in its latest financial filing.
Oncoceutics announced today that the first patient has been treated in a clinical trial of ONC201 for pediatric patients with brain tumors that contain a specific mutation called the histone H3 K27M mutation.
During its financial report this morning, Pfizer released an update of its pipeline which includes the discontinued projects.
Amgen’s migraine drug Aimovig continues to impress with its efficacy in late-stage studies.
PRESS RELEASES